EP1461068A4 - Methods of compositions for normalizing lipid levels in mammalian tissues - Google Patents

Methods of compositions for normalizing lipid levels in mammalian tissues

Info

Publication number
EP1461068A4
EP1461068A4 EP02803945A EP02803945A EP1461068A4 EP 1461068 A4 EP1461068 A4 EP 1461068A4 EP 02803945 A EP02803945 A EP 02803945A EP 02803945 A EP02803945 A EP 02803945A EP 1461068 A4 EP1461068 A4 EP 1461068A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
lipid levels
mammalian tissues
normalizing lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02803945A
Other languages
German (de)
French (fr)
Other versions
EP1461068A1 (en
Inventor
Garth James Smith Cooper
Kerry Martin Loomes
Rachel Nancy Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHILERA NEW ZEALAND Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Publication of EP1461068A1 publication Critical patent/EP1461068A1/en
Publication of EP1461068A4 publication Critical patent/EP1461068A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
EP02803945A 2001-11-26 2002-11-26 Methods of compositions for normalizing lipid levels in mammalian tissues Withdrawn EP1461068A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33342201P 2001-11-26 2001-11-26
US333422P 2001-11-26
NZ51573101 2001-11-26
NZ51573101 2001-11-26
PCT/NZ2002/000262 WO2003045424A1 (en) 2001-11-26 2002-11-26 Methods of compositions for normalizing lipid levels in mammalian tissues

Publications (2)

Publication Number Publication Date
EP1461068A1 EP1461068A1 (en) 2004-09-29
EP1461068A4 true EP1461068A4 (en) 2006-03-29

Family

ID=26652295

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02803945A Withdrawn EP1461068A4 (en) 2001-11-26 2002-11-26 Methods of compositions for normalizing lipid levels in mammalian tissues

Country Status (6)

Country Link
EP (1) EP1461068A4 (en)
JP (1) JP2005523418A (en)
CN (1) CN1617737A (en)
AU (2) AU2002356469A1 (en)
CA (1) CA2471833A1 (en)
WO (1) WO2003045424A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (en) 1998-09-25 2001-11-28 格利科克斯有限公司 Fructosamine oxidase: antagonists and inhibitors
DK1487431T3 (en) 2002-03-08 2012-08-20 Philera New Zealand Ltd Prevention and / or treatment of cardiovascular disease and / or associated heart failure
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
ES2449066T3 (en) 2004-07-19 2014-03-18 Philera New Zealand Limited Synthesis of triethylenetetramines
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
TWI646111B (en) 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 Anti-hyper-calcein gene-related peptide (ANTI-CGRP) composition and use thereof
KR102128628B1 (en) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
WO2012162257A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
AU2014285052B2 (en) * 2013-07-03 2019-09-12 H. Lundbeck A/S. Regulation of glucose metabolism using anti-CGRP antibodies
CR20210373A (en) 2019-01-08 2021-08-19 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309100A2 (en) * 1987-08-26 1989-03-29 Amylin Pharmaceuticals, Inc. Use of amylin or CGRP for the treatment of diabetes mellitus
WO1996004928A1 (en) * 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin gene related peptide receptor
EP0845269A2 (en) * 1996-11-29 1998-06-03 Weihan Wo Liposomal human calcitonin gene-related peptide composition and preparation of the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
AU6524794A (en) * 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
AU6596096A (en) * 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
WO1999040928A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309100A2 (en) * 1987-08-26 1989-03-29 Amylin Pharmaceuticals, Inc. Use of amylin or CGRP for the treatment of diabetes mellitus
WO1996004928A1 (en) * 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin gene related peptide receptor
EP0845269A2 (en) * 1996-11-29 1998-06-03 Weihan Wo Liposomal human calcitonin gene-related peptide composition and preparation of the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHATZIPANTELI K ET AL: "CALCITONIN GENE-RELATED PEPTIDE IS AN ADIPOSE-TISSUE NEUROPEPTIDE WITH LIPOLYTIC ACTIONS", ENDOCRINOLOGY AND METABOLISM, LONDON, GB, vol. 3, no. 4, 1996, pages 235 - 242, XP008057490, ISSN: 1074-939X *
HETTIARACHCHI M ET AL: "Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 273, no. 5 PART 1, November 1997 (1997-11-01), pages E859 - E867, XP002362126, ISSN: 0002-9513 *
MOORE MARY COURTNEY ET AL: "Insulin- and glucagon-independent effects of calcitonin gene-related peptide in the conscious dog", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 48, no. 5, May 1999 (1999-05-01), pages 603 - 610, XP002362125, ISSN: 0026-0495 *
See also references of WO03045424A1 *
YE J-M ET AL: "EVIDENCE THAT AMYLIN STIMULATES LIPOLYSIS IN VIVO: A POSSIBLE MEDIATOR OF INDUCED INSULIN RESISTANCE", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 280, no. 4, PART 1, April 2001 (2001-04-01), pages E562 - E569, XP009009879, ISSN: 0002-9513 *

Also Published As

Publication number Publication date
AU2002356469A2 (en) 2003-06-10
WO2003045424A1 (en) 2003-06-05
EP1461068A1 (en) 2004-09-29
JP2005523418A (en) 2005-08-04
AU2009201147A1 (en) 2009-04-23
CN1617737A (en) 2005-05-18
CA2471833A1 (en) 2003-06-05
AU2002356469A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
EP1380207A4 (en) Method of preserving mammalian organ
HK1079987A1 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
EP1660663A4 (en) Methods and compositions for tissue repair
HK1070830A1 (en) Hypotensive lipid and timolol compositions and methods of using same
HK1086738A1 (en) Regulation of mammalian keratinous tissue using hexamidine compositions
AU2003223416A1 (en) Tissue analogs for in vitro testing and method of use therefor
AU2003265010A1 (en) Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein
AU2001239873A1 (en) Adjuvant treatment by in vivo activation of dendritic cells
AU2002359949A1 (en) Compositions for improving lipid metabolism
AU2001238363A1 (en) Compositions for preventing cellulite in mammalian skin
EP1603932A4 (en) Methods and compositions for the enzymatic synthesis of gangliosides
EP1461068A4 (en) Methods of compositions for normalizing lipid levels in mammalian tissues
EP1476067A4 (en) Novel compositions and methods for cancer
AU7833601A (en) Charged lipid compositions and methods for their use
AU2001294820A1 (en) Methods for in vivo reduction of free radical levels and compositions useful therefor
EP1381839A4 (en) Method of imaging cell death in vivo
TWI367753B (en) Composition for normalization of infradian rhythm
EP1469769A4 (en) Novel compositions and methods for cancer
AU2003295692A1 (en) Methods and compositions for analysis of regulatory sequences
AU2002353078A8 (en) Tissue graft compositions and methods for producing same
AU2003215264A8 (en) Compositions and methods for delivery of skin cosmeceuticals
EP1469870A4 (en) Novel compositions and methods for cancer
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
EP1539199A4 (en) Methods and compositions for in vivo clearance of pathogens
AU2003263962A8 (en) Tissue compositions and methods for producing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069977

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20060210

17Q First examination report despatched

Effective date: 20070301

19U Interruption of proceedings before grant

Effective date: 20100713

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEMIX CORPORATION LIMITED

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1069977

Country of ref document: HK

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20111004

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHILERA NEW ZEALAND LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120204